Natera

Associate Medical Director - Breast

Remote

Not SpecifiedCompensation
Senior (5 to 8 years), Junior (1 to 2 years), Mid-level (3 to 4 years)Experience Level
Full TimeJob Type
UnknownVisa
Healthcare, Medical Devices, BiotechnologyIndustries

Requirements

Candidates must hold an M.D. or Ph.D., with at least 5 years of post-fellowship clinical experience in breast oncology, and a minimum of 3 years of clinical trial experience in academic, biotech, or pharmaceutical settings. They should possess at least 2 years of experience in Medical Affairs or Clinical Development roles with a proven track record in oncology, along with a willingness to travel more than 40% (primarily within the U.S., with occasional international travel).

Responsibilities

The Associate Medical Director will partner with the Medical Director, Oncology to develop and execute clinical strategies supporting Natera’s molecular diagnostic tools for breast cancer, including minimal residual disease (MRD) and ctDNA-based monitoring. They will lead the design and implementation of clinical studies and treatment protocols, recruit and engage principal investigators and clinical sites, advise on product development, provide post-launch medical affairs support, lead medical education initiatives, identify and recruit Key Opinion Leaders, support the publication strategy, and contribute to regulatory strategy, while ensuring compliance with Natera’s privacy and data security policies.

Skills

Clinical trial design
Regulatory frameworks
Biostatistics
Breast oncology treatment paradigms
Clinical guidelines
Diagnostic workflows
Leadership
Stakeholder engagement

Natera

Genetic testing and diagnostics solutions provider

About Natera

Natera focuses on genetic testing and diagnostics, providing advanced solutions for cancer patients, transplant patients, and individuals assessing hereditary health risks. Their main technology is cell-free DNA (cfDNA) testing, which analyzes DNA fragments in the blood to detect minimal traces of cancer and assess organ health. Natera stands out by offering specialized tests like the Signatera ctDNA test and Panorama NIPT, along with genetic counseling services. The company's goal is to improve patient care and health outcomes through accurate genetic testing.

Key Metrics

Austin, TexasHeadquarters
2004Year Founded
$149.9MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
1,001-5,000Employees

Benefits

Flexible medical plans
Investment options
Time off
Workplace perks

Risks

Hindenburg report accuses Natera of deceptive sales practices, risking legal challenges.
New Prospera Heart features may face slow adoption by healthcare providers.
Fetal RhD NIPT demand may drop post-RhIg shortage, affecting future sales.

Differentiation

Natera's Signatera test offers personalized ctDNA analysis for cancer patients.
Prospera Heart test uses unique Donor Quantity Score for transplant rejection detection.
Panorama NIPT test is a leader in non-invasive prenatal testing with 2 million tests.

Upsides

Increased adoption of liquid biopsy techniques boosts demand for Natera's cfDNA tests.
AI integration enhances accuracy and speed of Natera's cfDNA analysis.
Growing personalized medicine trend aligns with Natera's customized genetic tests.

Land your dream remote job 3x faster with AI